Compare related conditions and treatment approaches side-by-side. Understand trial availability, eligibility differences, and find the right clinical trial for your situation.
Both are inflammatory bowel diseases, but they differ in inflammation patterns, complications, and trial focus. Compare IBD trial availability, biologic options, and eligibility.
Women's cancers connected through BRCA mutations and hormonal pathways. Compare trial numbers, PARP inhibitor studies, biomarker testing, and tumour-agnostic options.
Both autoimmune, both treated with biologics and immunosuppressants โ but with very different organ involvement and trial landscapes. Compare RA and lupus trial options.
The two most common mental health conditions, frequently co-occurring. Compare psychedelic trials, neuromodulation studies, digital therapeutics, and treatment-resistant options.
Both smoking-related, both respiratory โ but cancer vs chronic disease requires fundamentally different trial approaches. Compare immunotherapy vs bronchodilator trials and biomarker requirements.
The two most common neurodegenerative diseases, each in a breakthrough era. Compare anti-amyloid vs gene therapy trials, biomarker testing, and early-stage trial opportunities.
Deeply connected conditions โ diabetes is the leading cause of CKD. Compare SGLT2 inhibitor trials, GLP-1 studies, and trials specifically for diabetic kidney disease.
Hypertension is the leading cause of heart failure. Compare cardiac device trials, renal denervation studies, and SGLT2 inhibitor research across both conditions.
The two most common chronic respiratory diseases. Compare biologic trials for severe asthma versus novel anti-inflammatory and stem cell trials for COPD.
Both progressive neurological conditions with very different trajectories. Compare DMT-rich MS trials with gene therapy-focused MND/ALS research and stem cell approaches.
The two most common chronic skin conditions, driven by different immune pathways. Compare Type 2 inflammation vs Th17/IL-23 biologic trials and JAK inhibitor research.
Major cardiovascular diseases with shared risk factors. Compare acute stroke interventions, rehabilitation tech, cardiac devices, and gene therapy across both conditions.
Two of the most common UK cancers with distinct biomarker landscapes. Compare PSA screening, FIT testing, radioligand therapy, and biomarker-driven trial eligibility.
Blood cancers with different origins โ bone marrow vs lymphatic system. Compare CAR-T therapy, targeted treatments, stem cell transplant trials, and precision medicine approaches.
Two prevalent neurological conditions with shared mechanisms. Compare CGRP inhibitor trials, neuromodulation devices, novel antiseizure medications, and gene therapy approaches.
Intimately connected โ chronic hepatitis drives liver cancer. Compare curative antiviral trials for HCV, functional cure research for HBV, and immunotherapy for hepatocellular carcinoma.
The two leading causes of irreversible sight loss in the UK. Compare IOP-lowering treatments, anti-VEGF injections, gene therapy, and neuroprotection trials for both conditions.
Intimately linked metabolic conditions transformed by GLP-1 therapies. Compare semaglutide, tirzepatide, and next-gen agonist trials for weight loss, glycaemic control, and remission.
Both mood disorders, but with fundamentally different treatment approaches. Compare mood stabiliser trials for bipolar with psychedelic and antidepressant innovation for MDD.
Trauma-triggered vs generalised anxiety โ overlapping symptoms with distinct trial pathways. Compare MDMA-assisted therapy for PTSD with broader anxiolytic approaches for anxiety.
The two most common neurodevelopmental conditions, co-occurring in 30โ50% of cases. Compare social cognition and sensory trials for autism with medication and digital therapy trials for ADHD.
Pain conditions with different mechanisms โ neuropathic vs neurovascular. Compare cannabis-based medicines and neuromodulation for chronic pain with CGRP inhibitors and devices for migraine.
Common respiratory conditions that frequently overlap. Compare CPAP alternatives and nerve stimulation for sleep apnoea with inhaled therapies and stem cell approaches for COPD.
Genetic vs inflammatory respiratory disease. Compare CFTR modulator and gene therapy breakthroughs for CF with biologics and precision medicine approaches for severe asthma.
Autoimmune vs metabolic diabetes โ fundamentally different diseases sharing high blood glucose. Compare cure-focused stem cell trials for T1D with GLP-1 revolution trials for T2D.
AF causes 1 in 5 strokes โ deeply connected cardiovascular conditions. Compare rhythm control and anticoagulation trials for AF with acute intervention and rehabilitation trials for stroke.
Umbrella term vs most common cause โ not all dementia is Alzheimer's. Compare anti-amyloid breakthroughs for Alzheimer's with multi-target approaches for vascular, Lewy body, and frontotemporal dementia.
Pain-driven vs fatigue-driven โ often co-occurring conditions with central sensitisation. Compare LDN, cannabinoids, and neuromodulation for fibromyalgia with antiviral and immunotherapy trials for ME/CFS.
Oil-driven vs immune-driven skin conditions โ the two most common dermatological complaints. Compare emerging biologics for acne with JAK inhibitor and microbiome revolution trials for eczema.
Both involve altered sensory processing and frequently co-occur. Compare neuromodulation and sound therapy trials for tinnitus with CGRP inhibitor and device trials for migraine.
Crystal-driven vs autoimmune joint disease โ different causes, similar pain. Compare new urate-lowering and anti-IL-1ฮฒ trials for gout with CAR-T cell and biosimilar biologics trials for RA.
Autoimmune gut damage vs functional bowel disorder โ overlapping symptoms, different biology. Compare gluten detoxification and desensitisation trials for coeliac with microbiome and hypnotherapy trials for IBS.
Tumour-driven vs central nervous system pain โ different WHO treatment pathways. Compare interventional procedures and cannabinoid trials for cancer pain with neuromodulation and digital therapy trials for chronic pain.
Androgen-driven vs oestrogen-driven gynaecological conditions โ both under-researched. Compare GLP-1 and anti-androgen trials for PCOS with GnRH antagonist and immunotherapy trials for endometriosis.
Oestrogen decline drives both โ menopause symptoms and bone loss are deeply connected. Compare NK3R antagonists and novel HRT for menopause with romosozumab and anabolic agents for osteoporosis.
Localised mechanical vs widespread central pain โ often confused. Compare regenerative medicine and CFT trials for back pain with LDN, cannabinoids, and neuromodulation trials for fibromyalgia.
Electrical vs structural heart disease โ each can cause the other. Compare pulsed field ablation and anticoagulation trials for AF with SGLT2 inhibitors and device therapy trials for heart failure.
Two fundamental cancer approaches โ immune activation versus cytotoxic cell killing. Compare checkpoint inhibitor trials with traditional chemotherapy studies across UK cancer types.
Advanced cell-based treatments for blood cancers. Compare engineered T-cell therapy with bone marrow transplantation โ mechanisms, eligibility, and UK trial availability.
Precision oncology versus broad cytotoxic treatment. Compare biomarker-driven targeted therapy trials with standard chemotherapy โ molecular testing, side effects, and trial design.
Correcting disease at the DNA level versus established management. Compare CRISPR and viral vector gene therapy trials with standard-of-care approaches across haemophilia, sickle cell, and more.
Exploiting DNA repair defects in BRCA/HRD tumours versus traditional cytotoxic treatment. Compare precision PARP inhibitor trials with chemotherapy for ovarian, breast, and prostate cancer.
Incretin-based therapies versus hormone replacement for diabetes and metabolic disease. Compare semaglutide, tirzepatide, and next-gen GLP-1 trials with insulin therapy studies.
Two pillars of autoimmune treatment โ injectable large molecules versus oral small molecules. Compare trial availability, administration routes, and side effect profiles for inflammatory diseases.
Hormone blockade versus cytotoxic treatment for cancer. Compare endocrine therapy and chemotherapy trials for breast cancer, prostate cancer, and other hormone-sensitive tumours.
Two advanced therapy approaches โ engineered cells versus genetic modification. Compare ex vivo cell engineering with in vivo gene delivery across oncology, haematology, and genetic disorders.
Our Smart Matcher asks about your situation and finds relevant trials โ no medical degree needed. Describe your symptoms, medications, and what you're looking for.
Open Smart Matcher